For ESA therapy in patients with solid tumors and hematologic malignancies, the guidelines recommend a target Hb level of 12 g/dL, initiated at <10 g/dL (symptomatic anemia) or <8 g/dL (asymptomatic anemia). Here, GSTM1 is linked to anemia (phenotype).